Could a diabetes drug shield the brain? early trial targets cognitive decline
NCT ID NCT06171152
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This early-phase study looks at whether liraglutide (Saxenda®), a drug used for weight loss, can increase a brain-protective protein called BDNF in people with multiple sclerosis, long-COVID, or acute leukemia (in remission) who also have obesity and memory or thinking problems. About 30 participants will take the drug for 8 weeks, with follow-up blood tests to measure BDNF levels. The goal is to gather initial data on whether this approach might help protect the brain, not to treat the underlying diseases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.